324 related articles for article (PubMed ID: 15127231)
1. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
3. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
4. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
Stathopoulos GP; Christodoulou Ch; Stathopoulos J; Skarlos D; Rigatos SK; Giannakakis T; Armenaki O; Antoniou D; Athanasiadis A; Giamboudakis P; Dimitroulis J; Georgatou N; Katis K
Cancer Chemother Pharmacol; 2006 Jun; 57(6):796-800. PubMed ID: 16142488
[TBL] [Abstract][Full Text] [Related]
6. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E
Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
8. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer.
Hoffman PC; Krauss SA; Drinkard LC; Masters GA; Samuels BL; Bitran JD; Golomb HM; Watson S; Vokes EE
Semin Oncol; 1995 Aug; 22(4 Suppl 9):38-41. PubMed ID: 7544026
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study.
Endo M; Takada Y; Obayashi K; Kotani Y; Satouchi M; Kado T; Sugimura K
Radiat Med; 2005 Aug; 23(5):331-5. PubMed ID: 16342905
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
15. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Hainsworth JD; Burris HA; Morrissey LH; Greco FA
Cancer; 1999 Mar; 85(5):1179-85. PubMed ID: 10091804
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
18. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
Fujiwara K; Ueoka H; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Sugimoto K; Shibayama T; Kamei H; Harita S; Okimoto N; Tanimoto M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):755-60. PubMed ID: 16208519
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
